Why Companies Still Struggle to Adopt CRISPR/Cas9
Across the biopharmaceutical industry, CRISPR/Cas9 remains difficult to deploy on a commercial level, because of the business realities around it.
1. A deeply fragmented IP landscape
Cas9 is covered by thousands of patents and at least 500+ unique applicants, with foundational patents extending to at least 2033. Even companies that secure multiple Cas9 licenses still face uncertainty, continual diligence, and the risk that additional rights may be required downstream.
2. Limited technology transfer and know-how
Most Cas9 licensors provide minimal hands-on support. As a result, organizations are left to build editing expertise internally, developing protocols from scratch, relying on scattered peer reviewed methods, and troubleshooting reproducibility challenges without guided technical transfer.
Removing Barriers to Industrial Gene Editing
Cas‑CLOVER® is a clean alternative to CRISPR/Cas9, purpose‑built for cell line development (CLD), cellular engineering, and bioprocessing. The system’s dimeric nuclease architecture enables high‑efficiency gene editing with markedly reduced off‑target activity, supporting reliable performance in production‑oriented workflows.
All components of the Cas‑CLOVER® system—including dCas9, guide RNAs, the Clo051 nuclease, and the overall platform architecture—are in‑licensed under a consolidated, conflict‑free IP position.
This unified intellectual property framework eliminates downstream uncertainty and supports confident progression from research to commercialization.
Demeetra’s licensing model maintains predictable costs, clear freedom to operate, and continuity of engineered cell lines across research, development, and GMP manufacturing, eliminating the need to rebuild clones due to technology switching. Licensing and deployment are supported by the same scientists who engineered and validated the platform, enabling efficient technology transfer that accelerates internal adoption and reduces operational risk.